Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Marinus Pharmaceuticals Inc (MRNS) Common Stock USD0.001

Sell:$2.80 Buy:$2.81 Change: $0.23 (7.57%)
Market closed |  Prices as at close on 21 February 2020 | Switch to live prices |
Sell:$2.80
Buy:$2.81
Change: $0.23 (7.57%)
Market closed |  Prices as at close on 21 February 2020 | Switch to live prices |
Sell:$2.80
Buy:$2.81
Change: $0.23 (7.57%)
Market closed |  Prices as at close on 21 February 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

Contact details

Address:
5 Radnor Corporate Center Suite 500
100 Matsonford Rd
RADNOR
19087
United States
Telephone:
+1 (484) 8014670
Website:
www.marinuspharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MRNS
ISIN:
US56854Q1013
Market cap:
$225.69 million
Shares in issue:
86.47 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Nicole Vitullo
    Chairman of the Board
  • Scott Braunstein
    President, Chief Executive Officer, Director
  • Joseph Hulihan
    Chief Medical Officer
  • Edward Smith
    Chief Financial Officer, Vice President, Treasurer, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.